IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases

• The mid-stage study aimed to evaluate the safety and pharmacokinetic/pharmacodynamic profile of INF904.
• Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study. 
• No safety concerns were identified in either of the two patient categories, the company said.
   

InflaRx N.V. (IFRX) announced on Monday that data from a mid-stage trial of its INF904 in certain skin conditions demonstrated positive outcomes, including a reduction in disease severity and pain, which sent shares rallying 62% in the pre-market session.

The company studied the experimental drug in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU). It was aimed at evaluating the safety and pharmacokinetics / pharmacodynamics profile of INF904.

While Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful, boil-like lumps to form under the skin, Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent, itchy hives (wheals) and/or swelling (angioedema) that lasts for six weeks or longer.

The company said that the data provide a strong rationale for further development of the drug in both these diseases.  

Mid-Stage Trial Results

Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study. 

In CSU, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients, particularly among those with severe disease. Urticaria Activity Score (UAS) is a patient-reported tool used to measure the severity of chronic hives (urticaria) by assessing the number of hives and the intensity of itch daily.

No safety concerns were identified in either of the two patient categories, the company said.

The company is now looking forward to initiating a Phase 2b trial in HS in 2026, while also engaging in dialogue with possible collaborators to advance the drug in CSU.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around IFRX stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.

IFRX stock is down 50% this year and by about 20% over the past 12 months. 

Also See: Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay

For updates and corrections, email newsroom[at]stocktwits[dot]com

Share

·

Add us on